|

PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

RECRUITINGSponsored by Novartis Pharmaceuticals
Actively Recruiting
SponsorNovartis Pharmaceuticals
Started2026-09-30
Est. completion2031-07-31
Eligibility
SexMALE
Healthy vol.Accepted

Summary

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer

Eligibility

Sex: MALEHealthy volunteers accepted
Inclusion criteria:

Age ≥ 18 years at index date

* Diagnosis of mPC
* PSMA positive
* Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date

Exclusion criterion:

• Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)

Conditions2

CancerMetastatic Prostate Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.